Skip to main content
. Author manuscript; available in PMC: 2014 Feb 3.
Published in final edited form as: JAMA. 2009 Oct 7;302(13):1429–1436. doi: 10.1001/jama.2009.1420

Table 2.

Incidence of End-Point Events for CYP2D6 Phenotypes Predicted by Genotype

Event No. (% in Subgroup)
EM (n = 609)a hetEM/IM (n = 637)a PM (n = 79)a
Local recurrence including second primary breast cancer 40 (6.6) 66 (10.4) 12 (15.2)
Distant recurrence 48 (7.9) 57 (8.9) 10 (12.7)
Overall recurrences 76 (12.5) 113 (17.7) 19 (24.1)
Death from any cause 102 (16.7) 114 (18.0) 18 (22.8)
Event-free survival eventb 135 (22.2) 176 (27.6) 26 (32.9)

Abbreviations: CYP, cytochrome P450; EM, extensive metabolism; IM, intermediate metabolism; PM, poor metabolism; UM, ultrarapid metabolism.

a

CYP2D6 phenotypes are defined as EM with 2 functional alleles (EM/EM, including UM), hetEM/IM with intermediate or 1 poor metabolism alleles (EM/IM, EM/PM, IM/IM, or IM/PM), and PM homozygous for poor metabolism alleles (PM/PM).

b

Event-free survival event was defined as the first event of local, regional, or distant recurrence; a second primary breast tumor; or death from any cause.